Want to see IBRX full AI Analyst Report?
IBRX Stock Chart & Stats
$8.19
-$0.30(-4.05%)
At close: 4:00 PM EDT
$8.19
-$0.30(-4.05%)
Day’s Range― - ―
52-Week Range$1.95 - $12.43
Previous CloseN/A
Volume8.52M
Average Volume (3M)8.44M
Market Cap
$8.56B
Enterprise Value$10.07K
Total Cash (Recent Filing)$357.37M
Total Debt (Recent Filing)$813.06M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding1,059,836,300
10 Day Avg. Volume7,700,462
30 Day Avg. Volume8,435,232
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.50Price Target Upside64.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$222.44M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginRapid revenue scaling shows that ANKTIVA is beginning to establish a commercial base, while the exceptionally high gross margin indicates substantial economic value per sale. If growth continues, this product economics could support improving operating leverage as fixed commercial costs are absorbed.
International Market ExpansionThe UAE approvals broaden ANKTIVA’s geographic reach and expand the addressable patient population across bladder and lung cancer indications. Regulatory validation in additional markets can create durable commercial opportunities, diversify revenue sources, and strengthen the product’s global positioning.
U.S. BCG Supply PositioningA long-term exclusive BCG supply agreement strengthens the commercial infrastructure supporting ANKTIVA in bladder cancer. More secure access to a required combination component can improve execution, support provider adoption, and reinforce ImmunityBio’s position in its approved treatment pathway.
Bears Say
Persistent Large LossesThe scale of ongoing losses shows that current revenue is not yet sufficient to support the company’s operating structure. Continued losses could delay the path to sustainable profitability, limit internally funded investment, and increase dependence on external financing while commercialization develops.
Negative Equity And Financing RiskA deeply negative equity position indicates a weak capital structure despite lower reported debt in the latest period. This reduces financial flexibility, leaves less balance-sheet capacity to absorb setbacks, and heightens the importance of obtaining additional capital to sustain operations and growth.
Persistent Cash BurnNegative operating and free cash flow means the business is not yet self-funding its activities. The deterioration in free cash flow suggests ongoing cash requirements remain substantial, potentially forcing continued reliance on external capital and constraining investment choices if funding conditions tighten.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.95 and its highest was $12.43 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $8.56B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Nov 05, 2026 which is in 59 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Aug 04, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.14.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.07.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 1,059,836,300 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -2.797%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.50 (64.84% Upside)
$13.50 (64.84% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 97%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 575.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
238.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ImmunityBio
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
IBRX Stock 12 Month Forecast
Average Price Target
$13.50
▲(64.84% Upside)
Technical Analysis
Ownership Overview
62.16% Insiders
4.06% Mutual Funds
2.29% Other Institutional Investors
24.17% Public Companies and
Individual Investors